Harbin Pharmaceutical Co., Ltd. announced that the daily closing price increase deviation value of the company's stock exceeded 20% for 2 consecutive trading days on September 21 and September 22, 2026, which is an abnormal fluctuation in stock trading. During this period, the company's stock rose and fell for 2 consecutive trading days, with a cumulative increase of 21.07%; as of the close of trading on September 21, the company's static price-earnings ratio was 57.46 times, significantly higher than the industry's static price-earnings ratio of 27.66 times that of the pharmaceutical manufacturing industry. There is a risk of irrational speculation and rapid decline. After self-inspection and verification with the controlling shareholders, there were no major changes in the company's fundamentals, production and operation were normal, there was no significant information that should be disclosed but not disclosed, and the controlling shareholders, directors and supervisors did not trade the company's shares during the change period.

Zhitongcaijing · 1d ago
Harbin Pharmaceutical Co., Ltd. announced that the daily closing price increase deviation value of the company's stock exceeded 20% for 2 consecutive trading days on September 21 and September 22, 2026, which is an abnormal fluctuation in stock trading. During this period, the company's stock rose and fell for 2 consecutive trading days, with a cumulative increase of 21.07%; as of the close of trading on September 21, the company's static price-earnings ratio was 57.46 times, significantly higher than the industry's static price-earnings ratio of 27.66 times that of the pharmaceutical manufacturing industry. There is a risk of irrational speculation and rapid decline. After self-inspection and verification with the controlling shareholders, there were no major changes in the company's fundamentals, production and operation were normal, there was no significant information that should be disclosed but not disclosed, and the controlling shareholders, directors and supervisors did not trade the company's shares during the change period.